Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1
Conditions: Hepatocellular Carcinoma Interventions: Drug: Alectinib (Alecensa), Nivolumab (Opdivo) Sponsors: China Medical University Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | China Health | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research